Itching for derm progress? We’ve got the cure.
The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research, and clinical pipelines facing intensifying competition, the need to develop differentiated, novel candidates has never been more critical.
As the field accelerates with clinical and commercial momentum, highlighted by Sanofi’s continued success with Dupixent, Corvus’ promising Phase 1 data on Soquelitinib, and landmark deals such as Gilead’s $1.7B inflammation partnership with LEO Pharma, this summit provides an essential platform to stay ahead of the curve. Returning this November, the meeting unites 120+ leading experts from pharma, biotech, and academia, all dedicated to overcoming the most pressing R&D bottlenecks in dermatology drug development.
If you’d like to learn more about the summit, download the event guide here: https://ter.li/yn0bqh
Showcasing the most novel targets, modalities, MoA, and delivery approaches, 2025 brings:
- End-to-end content: From early discovery and translational insights to clinical development, regulatory strategy, and commercial success
- The return of the Investor Stakeholder Panel: Hear what top investors are looking for and how to position your pipeline for funding and growth
- Breakthroughs in key indications: Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Prurigo Nodularis & more.
- Unmissable networking: Connect with decision-makers from Sanofi, Eli Lilly, Incyte, Galderma, AbbVie, and other major players
Top Speakers include:
- Ana Rossi, Global Senior Medical Director, Immunology, Sanofi
- Iva Igracki, Director, Medical Affairs Europe, Global Medical Lead, Innovative Dermatology Portfolio, Glenmark Pharmaceuticals
- Alexa Kimball, Chief Executive Officer & President, Harvard Medical Faculty Physicians
- Nidhi Malhotra, Principal Scientist & Director, Merck
- Ozge Uluckan, Senior Director, Disease Biology, Almirall
- Vanessa Morales-Tirado, Principal Scientist -Research, AbbVie
The program also offers a forward-looking exploration of the modalities reshaping dermatology pipelines, from bispecifics and biologics to oligonucleotides and beyond. By combining cutting-edge science with real-world clinical and strategic insights, the 9th Dermatology Drug Development Summit equips participants with the tools to accelerate innovation, navigate increasing competition, and ultimately deliver therapies that transform patient quality of life.
Have any questions? Get in touch here and we can arrange a quick call: https://ter.li/086xvl
